Untranslated

86-21-64556180

cpd-service@caerulumpharma.com

Home
About Us
Products
Solutions
FAQs
Contact Us

Home
Products
All products

Products Categories

Antineoplastic
- ACC
- Adenosine A2A
- ALK
- Androgen receptor inhibitor
- Apoptosis stimulant
- ATR
- AXL
- BCl2-BH4
- Bcr-Abl
- BRAF
- BTK
- CDK
- Chk1
- CYP17
- DNA alkylating agent
- EED
- EGFR
- EP4
- ER
- FAK
- FGFR
- FLT3
- Glutaminase
- IDO
- IRA
- KIT
- LXR
- MDM2
- MEK
- MET
- Nrf2
- P90RSK
- P97
- PAKS
- PARP
- PI3K
- Plk-1
- SMYD2
- SRC
- TOPK
- VEGFR
Hypoglycemic drugs
- DPP-4
- SGLT-1
- SGLT-2
Others
- 5HT
- AMPK
- Arginase
- CRF-1
- CXCR2
- FLAP
- FXR
- GABA
- Gi activator
- GR
- JAK
- LABA
- mAChRs
- NF-κB
- NRTI
- PPAR
- RIP1
- S1PR
- SGC
- SYK
- α2δ-1
- αIIbβ3
- β2-adrenoceptor
- σ1

All products

EAI-045
Poziotinib
Osimertinib Mesylate
BEC HCl
PRT-060318; PRT318; P142–76
BAY 61-3606 2HCl
GSK2256098
Flibanserin
MSC2530818
PQR530
Lanifibranor; IVA-337
AZD-5069
CYC-065
GDC-0077
IT-901
Allotetrahydroprogesterone
MDK7526 HCl
GSK2982772
THZ531
THZ2
CP-456773 sodium
T-26c
BAZ2-ICR
BAY-299
RGX-104 HCl
BLU-9931
2-(1H-imidazol-4-yl)pyridine HCl
CPDD2022
CPDD2021
CPDD2020

<< < Previous 29 30 31 32 33 34 Next > >> Page 33 / 34

Contact Us

3rd Floor, Building 4, 3918 Daye Road, Fengxian District, Shanghai
86-21-64556180
Within China:
sales-cpd@caerulumpharma.com
International:
cpd-service@caerulumpharma.com

Inquiry

For inquiries about our products, please leave your email with us and we will be in touch within 24 hours.Inquiry

Latest News

AstraZeneca receives regulatory boost for oncology drugs

AstraZeneca receives regulatory boost for...

AstraZeneca received a double boost for its oncology portfolio on Tuesday, after US and European regulators accepted regulatory submissions for its drugs, the first step towards winning approval for these medicines. ...

Top 7 Trends In Pharmaceutical Research In 2018

Top 7 Trends In Pharmaceutical Research I...

Being under ever-increasing pressure to compete in a challenging economic and technological environment, pharmaceutical and biotech companies must continually innovate in their R&D programmes to stay ahead ...

ARS-1620: A promising new inhibitor for KRAS-mutant cancers

ARS-1620: A promising new inhibitor for K...

According to a study published in Cell, researchers have developed a specific inhibitor for KRASG12C called ARS-1602 that induced tumor regression in mice. “This study provides in vivo evidence that mutant KRAS can be...

AstraZeneca receives regulatory boost for oncology drugs

AstraZeneca receives regulatory boost for...

AstraZeneca received a double boost for its oncology portfolio on Tuesday, after US and European regulators accepted regulatory submissions for its drugs, the first step towards winning approval for these medicines. ...

Top 7 Trends In Pharmaceutical Research In 2018

Top 7 Trends In Pharmaceutical Research I...

Being under ever-increasing pressure to compete in a challenging economic and technological environment, pharmaceutical and biotech companies must continually innovate in their R&D programmes to stay ahead ...

prev

next

© Copyright - 2010-2022 : All Rights Reserved.

FAQs
Downloadable
Contact Us

QR Code

WhatsApp Online Chat !

TOP

Previous Maximize